Aviatrix Automates Cloud Networking Within AWS Control Tower to Ensure Organizations Have a ‘Well-Architected’ Network Topology
25.8.2020 16:00:00 EEST | Business Wire | Press release
Aviatrix, the cloud network platform, today announced new capabilities to automate enterprise network infrastructure deployment and operations for organizations using the account factory feature of AWS Control Tower. Available now in AWS Marketplace, the integrated Aviatrix software serves as the network factory for newly provisioned accounts on Amazon Web Services (AWS). The solution helps enterprise organizations meet cloud governance and regulatory initiatives for their multi-account, multi-region cloud networks.
Join experts from Aviatrix and AWS on Thursday, August 27th as they host a live, online session to highlight the new AWS Control Tower and Aviatrix network factory capabilities. For more information or to register, go here.
“With AWS Control Tower, it only takes a few clicks for enterprise organizations to provision new AWS accounts that conform to company-wide policies,” said Chris Grusz, Director, AWS Marketplace, Amazon Web Services, Inc. “The Aviatrix cloud networking solution uniquely offers a network factory for AWS Control Tower. With AWS Control Tower account factory ensuring account control governance, customers will benefit from Aviatrix’s new capabilities that make certain the network infrastructure supporting those accounts is secure and correctly deployed every time.”
AWS Control Tower provides the easiest way to set up and govern new, secure, multi-account AWS environments. Additionally, AWS Service Catalog enables organizations to create and manage catalogs of approved IT services for use on AWS. The Aviatrix cloud network platform provides the prescriptive transit network architecture and operational visibility that meets enterprise cloud networking and security requirements. The Aviatrix software is able to create Amazon Virtual Private Clouds (Amazon VPCs), automate route table updates and ensure network correctness by preventing overlapping CIDRs, while also enforcing IT security controls through policy-based network segmentation. The integrated solution enables self-service delivery of new account infrastructure, provides detailed operational visibility, and helps ensure IT networking and security teams achieve compliance through a simple, automated workflow.
“In the journey to leverage cloud-based infrastructure we are always on the lookout for ways to streamline the automated delivery of services, in the simplest, most secure manner,” said Justin Donohoo, CTO at Observian. “The Aviatrix cloud network platform delivers the network architecture, advanced network, security controls, and operational visibility enterprises need. I view the integration of Aviatrix with AWS Control Tower as a natural evolution to streamline the delivery of new AWS infrastructure. Leveraging Aviatrix as the network factory and the AWS Control Tower account factory ensures that both AWS accounts and enterprise network infrastructure are deployed correctly and in compliance with corporate policies and industry regulations.”
Provisioning cloud network services is often easier than operationalizing them. AWS Control Tower customers who need to be in full control of their cloud network environment can also use the Aviatrix software to access the network intelligence they need – all in one place – instead of logging into multiple screens, services and management consoles to stitch together the network visibility they require. Aviatrix CoPilot – an available component of the integrated solution for AWS Control Tower - provides a global view of the cloud environment by leveraging intelligence and analytics from the Aviatrix cloud network platform combined with telemetry and network information gathered using native AWS APIs. CoPilot’s rich, intuitive visualizations provide actionable insights to practitioners by using dynamic multi-cloud topology maps, FlowIQ intelligent traffic flow analytics, global traffic heat maps, time series trend charts and a complete cloud network monitoring dashboard.
“AWS Control Tower is a leap forward for enterprise IT teams who are tasked with maintaining control over their networks, without becoming a bottleneck to their organization’s cloud agility and speed,” said Nauman Mustafa, VP of Solution Engineering at Aviatrix. “Regulatory compliance and corporate governance must be automated and adopted for the cloud era. The combination of AWS Control Tower and Aviatrix cloud network platform delivers the simplicity and automation along with enterprise visibility and control.”
Availability and How to Get Started
Aviatrix cloud network platform for AWS Control Tower is available immediately in AWS Marketplace. More technical information on the integrated solution - including how to get started - is available here. For a live demo or further information, please email info@aviatrix.com
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility required by enterprises with the simplicity and automation of cloud. More than 400 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at Aviatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005365/en/
Contact information
Aviatrix
Frank Cabri
frank@aviatrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
